Results 51 to 60 of about 44,633 (211)

Systemic Amyloidosis – Insights by Cardiovascular Magnetic Resonance [PDF]

, 2015
Systemic amyloidosis is the exemplar infiltrative, extracellular disease. Although it is a multi-organ disorder, cardiac involvement drives prognosis. Survival is worst in the AL amyloidosis subtype. It can affect any age and any race. There is no direct
Banypersad, SM
core  

Transthyretin Cardiac Amyloidosis: Pathogenesis, Treatments, and Emerging Role in Heart Failure with Preserved Ejection Fraction

, 2014
Transthyretin (TTR) amyloidosis causes heart failure from cardiac deposition of TTR amyloid fibrils, the by-product of TTR homotetramer disassembly. Wild-type (WT) TTR deposition leads to senile amyloidosis, predominantly manifesting with cardiomyopathy.
Daniel P. Judge, Van-Khue Ton, Monica Mukherjee   +2 more
core   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

New Medications in the Treatment of Hereditary Transthyretin Amyloidosis

, 2018
Hereditary transthyretin amyloidosis is an inherited disorder that results in the gradual progressive deposit of abnormal protein called amyloid in the body’s organs and tissues.
Scot Walker
core   +1 more source

The impact of limited healthcare access among patients with light chain and transthyretin amyloidosis: real-world survey during COVID-19 lockdown period in France

Orphanet Journal of Rare Diseases
Background The containment strategies during the COVID-19 pandemic between December 2019 and 2022 significantly disrupted the healthcare system. Cardiac amyloidosis has a poor prognosis and requires frequent follow-up in reference centres.
D. Guijarro, A. Jobbe-Duval, S. Aguilhon, F. Bauer, E. Donal, J. C. Eicher, J. Jeanneteau, B. Gellen, D. Kenizou, O. Lairez, B. Lequeux, D. Legallois, P. Réant, M. Salvat, M. F. Seronde, M. Kharoubi, A. Whereat, A. Farrugia, C. Taieb, A. Zaroui, T. Damy   +20 more
doaj   +1 more source

Cryptogenic ischemic stroke in cardiac transthyretin amyloidosis and sinus rhythm: a case report

Frontiers in Cardiovascular Medicine
Cardiac amyloidosis is a group of diseases characterized by the deposition of amyloid fibers in cardiac tissue. Two forms are mainly reported: light chain (AL) and transthyretin (ATTR) amyloidosis.
Angela Napolitano, Serena Toffanin, Cristiana Bulato, Elena Campello, Paolo Simioni, Luca Spiezia   +5 more
doaj   +1 more source

Lacrimal Gland Amyloidosis in an Elderly Patient

Case Reports in Ophthalmology, 2020
Localized amyloidosis of the lacrimal gland is a rare disease. We report a case of transthyretin-positive localized amyloidosis of the lacrimal gland in a 74-year-old man with left lacrimal gland swelling.
Toshiya Nagai, Tatsuya Yunoki, Atsushi Hayashi   +2 more
doaj   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Oligonucleotide Drugs for Transthyretin Amyloidosis [PDF]

New England Journal of Medicine, 2018
In this issue of the Journal, Adams et al.1 and Benson et al.2 report the results of two randomized, double-blind, controlled trials testing the therapeutic efficacy of two different chemically mod...
Adams, D, Hawkins, PN, Polydefkis, M
openaire   +6 more sources

A clinical case of hereditary transthyretin amyloidosis with predominant involvement of the peripheral nervous system

Анналы клинической и экспериментальной неврологии
Hereditary transthyretin amyloidosis is a fatal systemic progressive disease caused by mutations in the transthyretin (TTR) gene, inherited in an autosomal dominant pattern, primarily affecting the peripheral and autonomic nervous systems and the heart ...
Elizaveta A. Guseva, Natalia A. Suponeva, Marianna V. Mukhacheva   +2 more
doaj   +1 more source